2025
Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opiod use disorder in the United States
Ivasiy R, Madden L, Johnson K, Machavariani E, Ahmad B, Oliveros D, Tan J, Kil N, Altice F. Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opiod use disorder in the United States. International Journal Of Drug Policy 2025, 138: 104748. PMID: 40020306, PMCID: PMC12045481, DOI: 10.1016/j.drugpo.2025.104748.Peer-Reviewed Original ResearchConceptsOpioid use disorderSL-BUPXR-BUPUse disorderRetrospective cohort studyExtended-release buprenorphineReduce treatment discontinuationDays of supplyTreatment discontinuationSublingual buprenorphineReduce overdose riskBuprenorphine treatmentCohort studyHigh dosesPrimary outcomeImpact of dosagePatientsBuprenorphineMonthsMg/dayCommercially-insured individualsProportion of individualsOpioidOverdose riskImprove health outcomesExploration of the multi-level barriers to scaling up methadone for HIV prevention among people who inject drugs in Kazakhstan
Liberman A, Rozental Y, Ivasiy R, Kussainova A, Primbetova S, Madden L, Terlikbayeva A, Altice F. Exploration of the multi-level barriers to scaling up methadone for HIV prevention among people who inject drugs in Kazakhstan. Journal Of Substance Use And Addiction Treatment 2025, 172: 209640. PMID: 39986387, PMCID: PMC12009200, DOI: 10.1016/j.josat.2025.209640.Peer-Reviewed Original ResearchNominal group techniqueHIV preventionCommunity health workersMulti-level barriersIn-depth interviewsHealth workersPWID clientsSocioecological modelCommunity stakeholdersOpioid use disorderFocus groupsHIV epidemicClinical directorsClinical sitesEducating clientsOpioid agonist therapyImprove implementationGroup techniqueResearch teamCHWsPolicy levelUse disorderCliniciansAlternative medicationsEligibilityPrescribing methadone in prison predicts linkage to HIV care after release from prison: A randomized and patient preference trial
Mobley A, Wegman M, Bazazi A, Shenoi S, Bromberg D, Ahmad A, Kamarulzaman A, Altice F. Prescribing methadone in prison predicts linkage to HIV care after release from prison: A randomized and patient preference trial. International Journal Of Drug Policy 2025, 137: 104733. PMID: 39923270, PMCID: PMC11875876, DOI: 10.1016/j.drugpo.2025.104733.Peer-Reviewed Original ResearchConceptsLinkage to HIV careHIV careIncrease linkage to HIV careTreatment-as-prevention strategiesHIV treatment cascadeHIV treatment outcomesOpen-label trialCox proportional hazards modelsPatient preference trialOpioid use disorderMalaysia’s largest prison.Impact of methadoneProportional hazards modelTreatment cascadeInverse probability weighted Cox proportional hazards modelAnalytic sampleStudy participantsCareTreatment outcomesPrescribed methadoneOpioidConfounding variablesHIVUse disorderHazards modelRationale and design of a randomized clinical trial of integrated eHealth for PrEP and medications for opioid use disorders for women in the criminal legal system. The Athena study
Meyer J, Brunson S, Price C, Mulrain M, Nguyen J, Altice F, Kyriakides T, Cropsey K, Eaton E. Rationale and design of a randomized clinical trial of integrated eHealth for PrEP and medications for opioid use disorders for women in the criminal legal system. The Athena study. Addiction Science & Clinical Practice 2025, 20: 4. PMID: 39825419, PMCID: PMC11742507, DOI: 10.1186/s13722-024-00534-x.Peer-Reviewed Original ResearchConceptsCriminal legal systemOpioid use disorderLegal systemStandard of careStructural barriersUse disorderEnhanced standard of careRates of opioid use disorderDelivery of PrEPPre-exposure prophylaxisWomen's abilityRandomized clinical trialsLife-saving interventionsRandomized controlled trialsHealth disparitiesImplementation outcomesPrEP initiationPreventive servicesClinical outcomesIntegrated deliveryFollow-upDelivery modelsClinical trialsDecision aidPrEP
2024
Trajectory and progress of opioid agonist therapy programs in the Kyrgyz Republic
Liberman A, Kurmanalieva A, Biibosunova D, Shumskaya N, Ivasiy R, Bromberg D, Madden L, Altice F. Trajectory and progress of opioid agonist therapy programs in the Kyrgyz Republic. Global Health Economics And Sustainability 2024, 2: 2536. PMID: 40212662, PMCID: PMC11985161, DOI: 10.36922/ghes.2536.Peer-Reviewed Original ResearchOpioid agonist therapyHuman immunodeficiency virusMortality of human immunodeficiency virusOpioid agonist therapy programsOpioid use disorderMethadone programsHIV prevention strategiesAgonist therapyImmunodeficiency virusClinical protocolsEffective treatmentUse disorderNeighboring countriesHIV preventionKyrgyz RepublicMethadoneOpioidCentral AsiaIncreased state supportCentral Asian countriesDrugCarceral systemInternational donorsLocal news coveragePolitical challengesThe cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections
Ivasiy R, Madden L, DiDomizio E, Johnson K, Machavariani E, Ahmad B, Oliveros D, Ram A, Kil N, Altice F. The cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections. Drug And Alcohol Dependence 2024, 263: 112410. PMID: 39159600, PMCID: PMC12045330, DOI: 10.1016/j.drugalcdep.2024.112410.Peer-Reviewed Original ResearchOpioid use disorderXR-NTXUse disorderHCV infectionPrescribed MOUDOpioid use disorder cascadePrevalence of opioid use disorderRetrospective cohort studyHigher treatment retentionCascade of careConcurrent infectious diseasesSix-month retentionHCV/HIV coinfectionComorbid HIVCohort studyHospital-based settingPrescribed methadoneHCVMOUD initiationHIVHCV epidemicOpioidMethadoneMOUD prescriptionsTreatment retentionPrevalence and Correlates of Depression and Bipolar Disorder Among Patients Maintained on Methadone and Buprenorphine in Ukraine
Morozova O, Dvoriak V, Dumchev K, Machavariani E, Bromberg D, Dvoriak S, Altice F. Prevalence and Correlates of Depression and Bipolar Disorder Among Patients Maintained on Methadone and Buprenorphine in Ukraine. International Journal Of Mental Health And Addiction 2024, 1-18. DOI: 10.1007/s11469-024-01353-6.Peer-Reviewed Original ResearchCorrelates of depressionBipolar disorderUse disorderPrevalence of psychiatric disordersBurden of mental health disordersCo-occurring disordersAlcohol use disorderSubstance use disordersMental health disordersIntegrated care strategiesCluster randomized trialAnalyzed baseline dataOpioid use disorderPsychiatric disordersMethadone dosageDepression diagnosisStigma levelsPHQ-9Moderate/severe depressionHealth disordersDepressionCare strategiesPhysical healthDrug injectionDisordersHigher methadone dose at time of release from prison predicts linkage to maintenance treatment for people with HIV and opioid use disorder transitioning to the community in Malaysia
Ahmad A, Bromberg D, Shrestha R, Salleh N, Bazazi A, Kamarulzaman A, Shenoi S, Altice F. Higher methadone dose at time of release from prison predicts linkage to maintenance treatment for people with HIV and opioid use disorder transitioning to the community in Malaysia. International Journal Of Drug Policy 2024, 126: 104369. PMID: 38484531, PMCID: PMC11056294, DOI: 10.1016/j.drugpo.2024.104369.Peer-Reviewed Original ResearchMethadone maintenance treatmentNational Institute of Drug AbuseMethadone dosePost-releaseOpioid dependenceMaintenance treatmentMethadone maintenance treatment doseHigher doses of methadoneProspective trialsHighest methadone dosagePost-release outcomesHigher methadone dosesMalaysia’s largest prison.Levels of depressionTreatment of opioid use disorderMonths of releaseDose of methadoneOpioid use disorderLargest prisonHigher dosageIncarcerated peopleIncarceration periodUse disorderMethadone dosageTime-to-event analysisPreferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey.
Bromberg D, Madden L, Fraenkel L, Muthulingam D, Rhoades D, Dvoriak S, Dumchev K, Pykalo I, Altice F. Preferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey. PLOS Global Public Health 2024, 4: e0002725. PMID: 38277422, PMCID: PMC10817130, DOI: 10.1371/journal.pgph.0002725.Peer-Reviewed Original ResearchOpioid agonist therapyWithdrawal symptomsAdverse side effectsAgonist therapySide effectsOpioid use disorderQuality-of-life improvementUse disorderCombined HIVHIV incidenceClinical decision-makingDosing frequencyRespondent-driven samplingOpioidOpioid epidemicAssess preferencesClinical concernPatient preferencesPatientsDelivery strategiesTherapyDisordersHIVPatient concernsWithdrawal
2023
Qualitative exploration of the early experiences of opioid use disorder patients from private clinics after Russia’s invasion of Ukraine in five major cities in Ukraine
Mazhnaya A, Meteliuk A, Pykalo I, Altice F. Qualitative exploration of the early experiences of opioid use disorder patients from private clinics after Russia’s invasion of Ukraine in five major cities in Ukraine. Frontiers In Public Health 2023, 11: 1238188. PMID: 38162610, PMCID: PMC10756895, DOI: 10.3389/fpubh.2023.1238188.Peer-Reviewed Original ResearchConceptsPrivate clinicsOpioid use disorder patientsInvasion of UkraineOpioid use disorderDosage reductionTreatment optionsFull-scale invasion of UkraineHealth system navigationQualitative explorationExperiences of patientsQualitative semi-structured interviewsMOUD treatmentUse disorderPatientsRussia's invasion of UkraineFull-scale invasionDisorder patientsClinicState-funded clinicsSemi-structured interviewsMOUDMOUD deliveryMedication availabilityState-funded facilitiesPatient experienceHigh perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine
Galvez S, Altice F, Meteliuk A, Ivasiy R, Machavariani E, Farnum S, Fomenko T, Islam Z, Madden L. High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine. Frontiers In Public Health 2023, 11: 1231581. PMID: 38098837, PMCID: PMC10720365, DOI: 10.3389/fpubh.2023.1231581.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderAgonist therapyOAT patientsCOVID-19 pandemicSubstance useTake-home dosingAdditional psychosocial supportHigher perceived stressHigh riskPerceived Stress ScalePsychiatric disordersUse disordersPatientsPatient stressPsychosocial supportCertain subgroupsSevere levelsHigh levelsHealthcare deliveryStress ScalePerceived stressTherapyExtraordinary high levelsDisorders1901. High Prevalence of Latent Tuberculosis Infection in a Malaysian Prison
Zhang L, Shenoi S, Kamarulzaman A, Dhaliwal S, Ahmad A, Altice F. 1901. High Prevalence of Latent Tuberculosis Infection in a Malaysian Prison. Open Forum Infectious Diseases 2023, 10: ofad500.1729. PMCID: PMC10677608, DOI: 10.1093/ofid/ofad500.1729.Peer-Reviewed Original ResearchLatent tuberculosis infectionPrevalence of LTBIRisk of LTBITB preventive therapyIndependent risk factorTuberculin skin testC-reactive proteinActive TBPreventive therapyTuberculosis infectionRisk factorsHigh prevalenceMultivariable logistic regressionOpioid use disorderRisk of hepatotoxicityChest X-rayDrug use historyPaucity of dataLTBI treatmentHCV infectionHepatitis CHepatitis BMedian ageBlood testsSkin testAligning public health and public safety: Probation as a touchpoint to identify and link patients with opioid use disorder to opioid agonist treatment
Bromberg D, Galvez de Leon S, Litz T, Azbel L, Liberman A, Polonsky M, Dvoriak S, Saichuk N, Taxman F, Altice F. Aligning public health and public safety: Probation as a touchpoint to identify and link patients with opioid use disorder to opioid agonist treatment. PLOS Global Public Health 2023, 3: e0002349. PMID: 37910486, PMCID: PMC10619786, DOI: 10.1371/journal.pgph.0002349.Peer-Reviewed Original ResearchCriminal justice settingsOpioid use disorderBrief interventionUse disordersPrevalence of OUDProbation centersHIV prevention effortsJustice settingsMental healthHigh rateCommunity supervision settingsOAT servicesSBIRT interventionAgonist therapyHIV testingOpioid dependenceAgonist treatmentConsecutive individualsTreatment strategiesGeneral populationProbationSBIRTPrevention effortsSupervision settingParticipantsPreferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis
Muthulingam D, Hassett T, Madden L, Bromberg D, Fraenkel L, Altice F. Preferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis. Journal Of Substance Use And Addiction Treatment 2023, 154: 209138. PMID: 37544510, DOI: 10.1016/j.josat.2023.209138.Peer-Reviewed Original ResearchConceptsOpioid use disorderRoute of administrationPatient preferencesUse disordersSymptom reliefTreatment preferencesSide effectsCross-sectional observational studyTreatment-seeking peopleChi-squared analysisOral medicationsPublic health crisisOUD treatmentTreatment uptakeWithdrawal symptomsOpioid epidemicObservational studyTreatment decisionsSTROBE checklistSustainability of treatmentPatientsMedicationsHealth professionalsUtility scoresLarger studyLeveraging existing provider networks in Europe to eliminate barriers to accessing opioid agonist maintenance therapies for Ukrainian refugees
Nikitin B, Bromberg D, Madden L, Stöver H, Teltzrow R, Altice F. Leveraging existing provider networks in Europe to eliminate barriers to accessing opioid agonist maintenance therapies for Ukrainian refugees. PLOS Global Public Health 2023, 3: e0002168. PMID: 37440470, PMCID: PMC10343058, DOI: 10.1371/journal.pgph.0002168.Peer-Reviewed Original ResearchOpioid use disorderAgonist maintenance therapyMaintenance therapyInjection drug usePrevention of HIVGold standard treatmentRisk of HIVHigh prevalence ratesCare continuityStandard treatmentPrevalence ratesUse disordersImplementation science lensDrug useHarm reductionTreatment modelHIVPatientsClinicTherapyAddiction treatment modelsTreatmentProvidersInvasionInterview participants
2022
Impact of prerelease methadone on mortality among people with HIV and opioid use disorder after prison release: results from a randomized and participant choice open-label trial in Malaysia
Bazazi A, Culbert G, Wegman M, Heimer R, Kamarulzaman A, Altice F. Impact of prerelease methadone on mortality among people with HIV and opioid use disorder after prison release: results from a randomized and participant choice open-label trial in Malaysia. BMC Infectious Diseases 2022, 22: 837. PMID: 36368939, PMCID: PMC9652918, DOI: 10.1186/s12879-022-07804-6.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist therapyInfectious etiologyMost deathsUse disordersSample of menPrison releaseOpen-label trialT-lymphocyte countsPredictors of mortalityNational death recordsCrude mortality rateProportional hazards modelCovariate-adjusted modelsLow CD4Methadone initiationModified intentionAgonist therapySurvival benefitTreat analysisMethodsThis studyHIVHazards modelMortality rateMethadonePreliminary analysis of self-reported quality health indicators of patients on opioid agonist therapy at specialty and primary care clinics in Ukraine: A randomized control trial
Pashchenko O, Bromberg D, Dumchev K, LaMonaca K, Pykalo I, Filippovych M, Esserman D, Polonsky M, de Leon S, Morozova O, Dvoriak S, Altice F. Preliminary analysis of self-reported quality health indicators of patients on opioid agonist therapy at specialty and primary care clinics in Ukraine: A randomized control trial. PLOS Global Public Health 2022, 2: e0000344. PMID: 36962514, PMCID: PMC10021202, DOI: 10.1371/journal.pgph.0000344.Peer-Reviewed Original ResearchPrimary care clinicsOpioid use disorderOpioid agonist therapyPrimary careComplete self-reported dataPatient medical record dataMedical record dataComprehensive health outcomesAddiction treatment clinicsAdult PWIDAgonist therapySecondary outcomesParent trialPrimary outcomeRandomized participantsCare clinicsTreatment clinicsIntervention sitesUse disordersHealth outcomesAddiction treatmentRecord dataSelf-reported dataHealth indicatorsClinicUsing nominal group technique to identify barriers and facilitators to preventing HIV using combination same-day pre-exposure prophylaxis and medications for opioid use disorder
Eger WH, Altice FL, Lee J, Vlahov D, Khati A, Osborne S, Wickersham JA, Bohonnon T, Powell L, Shrestha R. Using nominal group technique to identify barriers and facilitators to preventing HIV using combination same-day pre-exposure prophylaxis and medications for opioid use disorder. Harm Reduction Journal 2022, 19: 120. PMID: 36307817, PMCID: PMC9616614, DOI: 10.1186/s12954-022-00703-8.Peer-Reviewed Original ResearchConceptsSame-day prescriptionPre-exposure prophylaxisOpioid use disorderHIV transmissionUse disordersClinical stakeholdersAvailability of providersSystems of careHealth care systemCoordinated careNew practice modelClinical careMedicationsPharmacy deliveryMOUDNominal group techniqueLocal prescribersPWIDSexual riskPrEPCare systemHealth benefitsCareMultiple visitsProphylaxisNurse Practitioner–Led Integrated Rapid Access to HIV Prevention for People Who Inject Drugs (iRaPID): Protocol for a Pilot Randomized Controlled Trial
Khati A, Altice FL, Vlahov D, Eger WH, Lee J, Bohonnon T, Wickersham JA, Maviglia F, Copenhaver N, Shrestha R. Nurse Practitioner–Led Integrated Rapid Access to HIV Prevention for People Who Inject Drugs (iRaPID): Protocol for a Pilot Randomized Controlled Trial. JMIR Research Protocols 2022, 11: e42585. PMID: 36222826, PMCID: PMC9597427, DOI: 10.2196/42585.Peer-Reviewed Original ResearchINTERNATIONAL REGISTERED REPORT IDENTIFIERSame-day PrEPHIV prevention programsPreliminary efficacyTrial designReal-world settingPrevention programsPre-exposure prophylaxis uptakePilot studyProspective pilot studySignificant public health concernOpioid use disorderHIV prevention strategiesHepatitis C virusOutbreak of HIVEvidence-based preventionPublic health concernInstitutional review boardMOUD initiationControlled TrialsPilot RCTC virusOpioid epidemicHIV preventionNurse practitionersStrengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection
Eller AJ, DiDomizio EE, Madden LM, Oliva JD, Altice FL, Johnson KA. Strengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection. Annals Of Medicine 2022, 54: 1714-1724. PMID: 35775786, PMCID: PMC9377256, DOI: 10.1080/07853890.2022.2084154.Peer-Reviewed Original ResearchConceptsCascade of careHuman immunodeficiency virusOpioid use disorderHepatitis C virusPublic health planningUse disordersCo-occurring opioid use disorderHealth planningBurden of diseaseSystems of careQuality improvement activitiesOUD cascadeTreatment initiationImmunodeficiency virusC virusPatient outcomesTreatment accessPayer sourceTreatment retentionHealth systemHealthcare systemCareSyndemicDisordersVirus
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply